# A Phase III Study of Apixaban in Patients With Atrial Fibrillation

> **NCT00496769** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 6421 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Acetylsalicylic acid

## Key facts

- **NCT ID:** NCT00496769
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-31
- **Primary completion:** 2010-11-30
- **Final completion:** 2017-05-25
- **Target enrollment:** 6421 (ACTUAL)
- **Last updated:** 2018-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00496769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00496769, "A Phase III Study of Apixaban in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00496769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*